NasdaqGS:ABCLLife Sciences
A Look At AbCellera Biologics (ABCL) Valuation After Bruker Settlement And Board Appointment
AbCellera Biologics (ABCL) has drawn fresh attention after settling a dispute with Bruker Corporation that brings in a US$36 million upfront payment plus future royalties, and it has also added scientist Stephen Quake to its board.
See our latest analysis for AbCellera Biologics.
The recent legal settlement and board appointment come on the back of a 7 day share price return of 27.41% and a year to date share price return of 27.41%. The 1 year total shareholder return of 49.66% contrasts with...